Schilogy over 50 years of age is high, and the domestic vaccine market space is huge

"Pain is like a needle tie, knife cutting and tearing, and it will also be accompanied by a burning sensation. The pain is continuous and fatal, and even the breathing is painful. Sometimes the clothes accidentally encounter the affected area, and the pain will increase ..." Mr. Wang will go to Guangzhou Daily · Xinhuacheng reporter still feels "scared" when he is suffering from shingles, and he is less than 40 years old when he becomes sick. In fact, acute infectious skin diseases caused by the re -activation of chickenpox belt -shaped virus (VZV), shingles are relatively high among middle -aged and elderly people over 50 years old. The most common complications are "after zoster "Nervous pain", about 9%to 34%of patients with shingles have potential risks of such neuralgia. Although shingles are not fatal, pain may torture some patients for up to 10 years. Recently, the domestic -produced shingles vaccine -related R & D news has once again attracted everyone's attention to shingles.

People over 50 years of age are more likely to infected with shingles

"There are some ways to prevent people from infected with shingles, and vaccination is the most effective way. This is a method that introduces the activated virus into the body to stimulate the immune system to produce antibodies against the virus. People can consider inoculating shingles vaccine. "Some experts said.

As the elderly people who are more likely to infect shingles are growing, the incidence of shingles in China is getting higher and higher. According to the information of Fhstrilin, new shingles of herpes zoster in China increased from 2.5 million in 2015 to 3.9 million in 2015, with a compound annual growth rate of 7.8%. It is expected to be in 2025 The increase of 4.9 million cases; the annual growth rate from 2021 to 2025 was 6%, and it would be further increased to 6 million by 2030, and the compound annual growth rate from 2025 to 2030 was 4.2%.

As the public's understanding of shingles has continuously increased and the number of available shingles vaccine products increases, China's shingles vaccine market is expected to expand significantly. According to Ferris Sanderian data, according to sales revenue, the Chinese shingles vaccine market increased from zero in 2015 to RMB 600 million in 2021, and it is expected to increase in 2025 to 10.8 billion yuan, 2021 in 2021 By 2025, the compound annual growth rate was 103.8%, and it would further increase to RMB 28.1 billion in 2030, and the compound annual growth rate from 2025 to 2030 was 21.1%.

The domestic vaccine market space is huge

Sedic vaccine is considered to be another "dark horse" in the vaccine field after HPV vaccine. Not only will the future sales space be huge, but also the applicable population may move forward. Huaxi Securities Research Report estimates that the applicable population of foreign vaccines that have been approved in China at present is over 50 years old. Domestic enterprises have the clinical trials of herpes herpes to reduce the live vaccine of herpes. The market space of herpes zoster vaccine over 40 years of age can reach 30 billion yuan.

Debon Securities Research reports that there are about 690 million people over the age of 40 in my country. As consumption upgrades and vaccination awareness will increase, people will have a high degree of vaccination in the future. However, due to a variety of factors, at present, foreign vaccines are very low in domestic penetration. The huge domestic herpes zoster vaccine needs still need to rely on cost -effective products to meet.

Beijing Green Bamboo Biotechnology Co., Ltd. recently submitted a listing application on the Hong Kong Stock Exchange. According to the prospectus, green bamboo biological is committed to human vaccine and therapeutic biological agents. At present, there are no products on sale. In 2020 and 2021, net losses were 174 million yuan and 539 million yuan, respectively. As shingles have attracted more and more people's attention in recent years, the zoster -shaped vaccine of green bamboo creatures has attracted public attention. Green Bamboo Bio said that LZ901 is the company's independent reorganized band -shaped shingle candidate vaccine and one of the company's core products. It is expected to complete the second phase of clinical trials in the fourth quarter of 2022, and has submitted an IND application to the US FDA. It is China's first China. The model and the only shingles vaccine seeking global filing.

It is reported that the only domestic shingles vaccine in China is the SHINGRIX of GlaxoSmithg, which is a reorganized vaccine, with a price of up to 1600 yuan/dose, and a two doses of 3,200 yuan. 500 yuan to 800 yuan/needle, each course of treatment is injected with two stitches, the price advantage is more obvious.

Text/Guangzhou Daily · Xinhuacheng Reporter: Tu Duanyu Title Picture/Xinhua News Agency Guangzhou Daily · Xinhuacheng Editor: Long Chengliu

- END -